Cambium Bio Limited Cambium Bio Limited

Cambium Bio Limited

CMB

Rang in aandelen #32543
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Aandeelprijs
$0.31737816
Marktkapitalisatie
$9.34M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
5,917.33%
Land
AU
Handel Cambium Bio Limited (CMB)

Categorie

Healthcare
Dividendrendementgeschiedenis voor Cambium Bio Limited (CMB)
Het dividendrendement (TTM) van Cambium Bio Limited (aandelsymbool: CMB) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Cambium Bio Limited (CMB) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL